Loading stock data…
IDYA
$28.13-0.19 (-0.67%)
Market ClosedLast close May 11
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IDEAYA Biosciences, Inc. in the Healthcare sector is trading at $28.13. The stock is currently 28% below its 52-week high of $39.28, remaining 8.0% below its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why IDYA maintains its current current market pressure. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.13
Potential Upside
5%
Whystock Fair Value$29.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$52.75+87.5%
Range$36.00 – $81.00
Fundamentals
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and sel...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.44%
Volume
Today's trading volume
980,354
Recent News
Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time Review
IDEAYA Biosciences (IDYA) is back in focus after reporting positive topline Phase 2/3 OptimUM-02 data for its darovasertib plus crizotinib regimen in first line metastatic uveal melanoma and securing FDA Real-Time Oncology Review. See our latest analysis for IDEAYA Biosciences. The positive darovasertib data and Real-Time Oncology Review sit against a mixed share price picture, with recent 1-month and year-to-date share price declines but a 1-year total shareholder return of 61.19% suggesting...
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -3.35% and -35.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?
Is IDYA a good stock to buy? We came across a bullish thesis on IDEAYA Biosciences, Inc. on Valueinvestorsclub.com by pestopenguin. In this article, we will summarize the bulls’ thesis on IDYA. IDEAYA Biosciences, Inc.’s share was trading at $29.48 as of April 27th. IDYA’s forward P/E was 4.65 according to Yahoo Finance. Ideaya Biosciences is positioned […]
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. IDEAYA Biosciences, Inc. is among the best biotech stocks to invest in. TheFly reported on April 14 that Wedbush Securities increased its price target on IDYA from $52 to $58 while maintaining an Outperform rating. The update followed the […]
Novo teams with OpenAI; Ideaya gets muted response to eye drug data
Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into radiopharmaceuticals and a GSK cancer drug showed early promise.